Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert I. Haddad, Marshall R. Posner, Anne O’Neill et al.|The Lancet Oncology|2013Cited by 748
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Naifa L. Busaidy et al.|Clinical Cancer Research|2018Cited by 125
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women’s Cancer Center Multidisciplinary GuidelineAhmed S. Sultan, Hani Mawardi, Glenn J. Hanna et al.|The Oncologist|2017Cited by 96
Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literatureGuilherme Rabinowits, Robert I. Haddad|Oral Oncology|2012Cited by 87
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancerVishwajith Sridharan, Jonathan D. Schoenfeld, Danielle N. Margalit et al.|British Journal of Cancer|2016Cited by 85